339 related articles for article (PubMed ID: 17011186)
1. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
van Dalen EC; van den Brug M; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
3. Monitoring for anthracycline cardiotoxicity.
Lipshultz SE; Sanders SP; Goorin AM; Krischer JP; Sallan SE; Colan SD
Pediatrics; 1994 Mar; 93(3):433-7. PubMed ID: 7818624
[TBL] [Abstract][Full Text] [Related]
4. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
van Dalen EC; Caron HN; Kremer LC
Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group.
Steinherz LJ; Graham T; Hurwitz R; Sondheimer HM; Schwartz RG; Shaffer EM; Sandor G; Benson L; Williams R
Pediatrics; 1992 May; 89(5 Pt 1):942-9. PubMed ID: 1579408
[TBL] [Abstract][Full Text] [Related]
7. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
8. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
Orditura M; De Vita F; Ciaramella F; Catalano G
Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
[TBL] [Abstract][Full Text] [Related]
9. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
Lopez M; Vici P
Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
[TBL] [Abstract][Full Text] [Related]
10. An introduction to the metabolic determinants of anthracycline cardiotoxicity.
Menna P; Recalcati S; Cairo G; Minotti G
Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
12. The role of biomarkers in the early detection of anthracycline-induced cardiotoxicity in children: a review of the literature.
Mavinkurve-Groothuis AM; Kapusta L; Nir A; Groot-Loonen J
Pediatr Hematol Oncol; 2008 Sep; 25(7):655-64. PubMed ID: 18850478
[TBL] [Abstract][Full Text] [Related]
13. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
14. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
16. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
17. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Vejpongsa P; Yeh ET
J Am Coll Cardiol; 2014 Sep; 64(9):938-45. PubMed ID: 25169180
[TBL] [Abstract][Full Text] [Related]
18. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.
Watts RG; George M; Johnson WH
Cancer; 2012 Apr; 118(7):1919-24. PubMed ID: 21882180
[TBL] [Abstract][Full Text] [Related]
20. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
